Lexology August 9, 2023
McDermott Will & Emery

Key players across the healthcare industry—including sponsors, contract research organizations (CROs), research sites, regulators and patient advocates—are well aware of the challenges associated with the prompt and effective identification and enrollment of study subjects. In this context, stakeholders should consider several important factors when developing and implementing study pre-screening and recruitment activities.

In Depth

Delays or failures in launching clinical trials can lead to millions of dollars in costs for sponsors and impede access to new or improved therapies and diagnostics for patients. As services and initiatives designed to address these challenges proliferate, it is important to consider key factors that can trigger legal, operational and business risks.

  1. Data Use and Sharing. It is important to consider what data...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Clinical Trials, FDA, Govt Agencies, HIPAA, Trends
mRNA Vaccine Shows Promise In Pancreatic Cancer Trial
AI Enhances Breast Cancer Detection in Screening Trial
Can innovation in clinical trial delivery meet the demands of increasing complexity in drug development?
Podcast: How Trump’s tariffs will impact clinical trials
AI screening for heart failure clinical trial speeds up enrollment, study finds

Share This Article